Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
F 73.26 -0.58% -0.43
GILD closed down 0.58 percent on Monday, March 18, 2024, on 77 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Upper Bollinger Band Walk Strength -1.28%
Overbought Stochastic Strength -1.28%
Gapped Down Weakness -1.28%
Upper Bollinger Band Walk Strength -2.54%
Weak + Overbought Other -2.54%
Above Upper BB Strength -2.54%
Gapped Up Strength -2.54%
Overbought Stochastic Strength -2.54%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 10 hours ago
60 Minute Opening Range Breakout about 11 hours ago
10 DMA Support about 13 hours ago
Fell Below Previous Day's Low about 15 hours ago
Fell Below 10 DMA about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Gilead Sciences, Inc. Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biopharmaceutical Nasdaq 100 Disease Inflammation Infection Cardiovascular Disease Hypertension Antibiotics Coronavirus Influenza Macular Degeneration Vascular Disease Respiratory Diseases Pulmonary Arterial Hypertension Cystic Fibrosis Liver Disease HIV Immunodeficiency Perfusion Oligonucleotide Organic Chemistry Hepatotoxins Angina Gilead Sciences Prodrugs Retinitis Treatment Of Cardiovascular Disease Cytomegalovirus Retinitis Fungal Infection Fungal Infections Myocardial Perfusion Imaging Oncology Diseases Tenofovir Disoproxil Treatment Of Cardiovascular Diseases

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 86.9592
52 Week Low 70.6463
Average Volume 7,022,582
200-Day Moving Average 75.86
50-Day Moving Average 76.37
20-Day Moving Average 72.81
10-Day Moving Average 73.66
Average True Range 1.23
RSI (14) 46.52
ADX 20.96
+DI 24.67
-DI 22.10
Chandelier Exit (Long, 3 ATRs) 71.73
Chandelier Exit (Short, 3 ATRs) 74.34
Upper Bollinger Bands 75.13
Lower Bollinger Band 70.48
Percent B (%b) 0.6
BandWidth 6.38
MACD Line -0.31
MACD Signal Line -0.70
MACD Histogram 0.3963
Fundamentals Value
Market Cap 91.28 Billion
Num Shares 1.25 Billion
EPS 4.50
Price-to-Earnings (P/E) Ratio 16.28
Price-to-Sales 3.39
Price-to-Book 4.04
PEG Ratio 0.42
Dividend 3.00
Dividend Yield 4.10%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 74.71
Resistance 3 (R3) 74.85 74.51 74.47
Resistance 2 (R2) 74.51 74.14 74.44 74.39
Resistance 1 (R1) 73.89 73.91 73.72 73.74 74.31
Pivot Point 73.55 73.55 73.46 73.47 73.55
Support 1 (S1) 72.92 73.18 72.75 72.78 72.21
Support 2 (S2) 72.58 72.95 72.51 72.13
Support 3 (S3) 71.96 72.58 72.05
Support 4 (S4) 71.81